StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) shareholders

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.44+0.03 (+2.13%)

Close on Nov 17, 2026Market cap $120.11MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
40.9%
34M of 83M shares
Institutional holders
76
9 new, 10 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
1 buys · 1 sales
Net sold $107.10K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
GordonMD Long Biased Master Fund LP
Joint filing with GordonMD Global Investments LP (17.50%), GordonMD Long Biased GP LLC (17.50%) and 1 more
27,988,71417.50%13G (passive) amendmentOct 1, 2026
GordonMD Global Investments LP
Joint filing with GordonMD Long Biased Master Fund LP (16.40%), GordonMD Long Biased GP LLC (16.40%) and 1 more
20,441,94816.40%13G (passive) amendmentOct 1, 2026
GordonMD Long Biased GP LLC
Joint filing with GordonMD Global Investments LP (12.10%), GordonMD Long Biased Master Fund LP (12.10%) and 1 more
10,024,90912.10%13G (passive) amendmentJun 30, 2026
Bvf Inc/Il
Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more
8,336,9029.99%13G (passive)Jul 2, 2026
Lara Sullivan, M.D.7,543,00711.21%13D (active) amendmentMar 31, 2025
Lara Sullivan6,624,69910.30%13D (active) amendmentDec 23, 2024
Coastlands Capital LP
Joint filing with Coastlands Capital Partners LP (5.42%), Coastlands Capital GP LLC (5.42%) and 2 more
6,448,9075.42%13G (passive)Oct 1, 2026
Benjamin Alexander Smith
Joint filing with Laurion Capital Management LP (7.72%), Janaka Sheehan Maduraperuma (7.72%)
4,796,4797.72%13G (passive) amendmentDec 31, 2025
Janaka Sheehan Maduraperuma
Joint filing with Laurion Capital Management LP (5.16%), Benjamin Alexander Smith (5.16%)
4,300,8885.16%13G (passive) amendmentSep 30, 2026
Millennium Group Management LLC
Joint filing with Millennium Management LLC (5.70%), Israel A. Englander (5.70%)
3,542,6635.70%13G (passive)Jun 27, 2025
Millennium Management LLC
Joint filing with Millennium Group Management LLC (5.30%), Israel A. Englander (5.30%) and 1 more
3,160,1395.30%13G (passive)Dec 9, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PYXSValueChange% of portfolio
GordonMD Global Investments LP10,024,90912.02%$30.17M+5,903,03914.60%
Pfizer Inc7,032,7708.43%$19.48M–11.43%
Laurion Capital Management LP4,900,8885.88%$14.75M−96,4450.38%
Vanguard Capital Management LLC2,075,9972.49%$6.25M+42,4870.00%
HealthInvest Partners AB966,4591.16%$2.91M+769,4230.78%
BlackRock, Inc.867,9341.04%$2.61M+79,0950.00%
Palo Alto Investors LP864,2771.04%$2.60M−146,2330.36%
Marshall Wace, Llp830,5441.00%$2.50M+476,1270.00%
Renaissance Technologies LLC772,2320.93%$2.32M−116,4480.00%
Geode Capital Management, LLC591,8490.71%$1.78M−6,2720.00%
Woodline Partners LP523,9990.63%$1.58MNew0.00%
683 Capital Management, LLC459,3670.55%$1.38M−436,8960.07%
Jacobs Levy Equity Management, Inc428,6060.51%$1.29M−32,3910.00%
Longaeva Partners L.P.353,5820.42%$1.06M−149,6320.02%
Decheng Capital LLC326,8100.39%$983.70K–0.13%
Vanguard Fiduciary Trust Co302,9860.36%$911.99K+2,0890.00%
Jane Street Group, LLC290,0900.35%$873.17K−14,3690.00%
State Street Corp248,8370.30%$749.00K–0.00%
Millennium Management LLC233,0040.28%$701.34K−164,6210.00%
UBS Group AG155,2170.19%$467.20K−98,9070.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20267634M40.9%9 / 2424 / 108M2M
Q1 20267828M33.1%14 / 1136 / 144M4M
Q4 20257930M36.2%22 / 2419 / 149M6M
Q3 20257327M32.2%14 / 1131 / 155M5M
Q2 20257428M33.0%15 / 2123 / 304M7M
Q1 20258930M36.3%13 / 2226 / 222M4M
Q4 20249932M37.8%25 / 3220 / 1812M8M
Q3 20249228M33.5%23 / 2917 / 97M5M
Q2 20248028M33.8%25 / 2021 / 168M2M
Q1 20247123M27.6%30 / 225 / 915M1M
Q4 2023519M10.6%9 / 1112 / 112M1M
Q3 2023548M9.4%14 / 1513 / 71M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

17 funds held PYXS in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of PYXSValue% of fundAs of
Vanguard Total Stock Market Index Fund1,422,2961.71%$4.28M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund558,7750.67%$1.68M0.00%Jun 30, 2026
iShares Biotechnology ETF374,6800.45%$1.13M0.01%Jun 30, 2026
Fidelity Extended Market Index Fund271,5450.33%$488.78K0.00%May 31, 2026
iShares Micro-Cap ETF166,5640.20%$501.36K0.03%Jun 30, 2026
Fidelity Total Market Index Fund90,2760.11%$162.50K0.00%May 31, 2026
Fidelity Series Total Market Index Fund78,7090.09%$141.68K0.00%May 31, 2026
Ultra-Small Company Market Fund70,0600.08%$210.88K0.14%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund38,0720.05%$68.53K0.00%May 31, 2026
Vanguard Balanced Index Fund26,8660.03%$80.87K0.00%Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund26,6500.03%$80.22K0.00%Jun 30, 2026
1290 VT Micro Cap Portfolio11,1880.01%$33.68K0.02%Jun 30, 2026
U.S. Micro Cap Portfolio10,2630.01%$27.20K0.00%Jul 31, 2026
Victory Extended Market Index Fund5,9680.01%$15.82K0.00%Jul 31, 2026
JNL/DFA U.S. Small Cap Fund3,9220.00%$11.81K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Thomas CivikCEO & Chairman of the Board, Director221,8860.27%Sep 8, 2026
Lara SullivanPresident ,CEO & CMO, Director2,403,8822.88%Apr 2, 2025
Jitendra WadhanePrin Fin & Acct Officer512,8820.61%Mar 25, 2026
Pamela Ann ConnealyCFO & COO3,425,1794.11%Apr 2, 2025
Rachel HumphreyDirector81,3090.10%Nov 6, 2026
Jakob DupontDirector73,7410.09%Aug 20, 2026
Santhosh PalaniDirector6,0000.01%Mar 25, 2026
Michael A. MetzgerDirector––Mar 25, 2026
Freda C. Lewis-HallDirector241,4050.29%Mar 25, 2026
John L. FlavinDirector413,0150.50%Mar 25, 2026
Darren S. ClineDirector251,4050.30%Mar 25, 2026
Long Biased Master Fund LP GordonMD10% owner––Oct 9, 2026
Long Biased GP LLC GordonMD10% owner10,024,90912.02%Oct 9, 2026
Craig D. Gordon10% owner––Oct 9, 2026
Global Investments LP GordonMD10% owner15,541,90918.63%Oct 9, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Global Investments LP GordonMD
10% owner
Oct 1, 2026Buy+5,517,000––15,541,909
Jakob Dupont
Director
Jun 30, 2026Option exercise+35,000$1.60$56.00K73,741
Jakob Dupont
Director
Jun 30, 2026Sale(10b5-1 plan)−35,000$3.06$107.10K38,741
Jitendra Wadhane
Prin Fin & Acct Officer
Mar 24, 2026Award+109,461––512,882
Rachel Humphrey
Director
Apr 21, 2025Sale(10b5-1 plan)−13,896$1.03$14.31K81,309
Rachel Humphrey
Director
Apr 17, 2025Sale(10b5-1 plan)−200$0.97$19495,205
Rachel Humphrey
Director
Apr 14, 2025Sale(10b5-1 plan)−1,400$0.97$1.36K95,405
Pamela Ann Connealy
CFO & COO
Nov 26, 2024Buy+83,400$1.96$163.46K1,199,143
Pamela Ann Connealy
CFO & COO
Nov 26, 2024Buy+5,450$2.00$10.90K1,115,743
Santhosh Palani
Director
Jun 7, 2024Award+6,000––6,000
Freda C. Lewis-Hall
Director
Mar 26, 2024Award+35,219––241,405
Jitendra Wadhane
SVP, Chief Accounting Officer
Mar 26, 2024Award+131,484––398,421
Rachel Humphrey
Director
Mar 26, 2024Award+38,741––96,805
John L. Flavin
Director
Mar 26, 2024Award+35,219––413,015
Jakob Dupont
Director
Mar 26, 2024Award+38,741––38,741
Pamela Ann Connealy
CFO & COO
Mar 26, 2024Award+328,710––1,110,293
Darren S. Cline
Director
Mar 26, 2024Award+35,219––251,405
Pamela Ann Connealy
CFO and COO
Nov 29, 2023Tax withholding−36,949$1.40$51.73K781,583
Jitendra Wadhane
Chief Accounting Officer
Nov 15, 2023Award+40,000––266,937
Pamela Ann Connealy
CFO and COO
Sep 28, 2023Buy+8,000$1.87$14.96K818,532
Pamela Ann Connealy
CFO and COO
Sep 27, 2023Buy+6,426$1.85$11.89K810,532
Jitendra Wadhane
Chief Accounting Officer
Sep 27, 2023Buy+2,500$1.87$4.68K226,937
Pamela Ann Connealy
CFO and COO
Sep 25, 2023Buy+12,000$1.67$20.04K804,106
Jitendra Wadhane
Chief Accounting Officer
Sep 25, 2023Buy+5,000$1.77$8.85K224,437
Jitendra Wadhane
Chief Accounting Officer
Sep 22, 2023Buy+2,500$1.74$4.35K219,437
Pamela Ann Connealy
CFO and COO
Sep 22, 2023Buy+5,000$1.74$8.70K792,106
Lara Sullivan
President and CEO, Director
Sep 18, 2023Sale−8,541$2.10$17.94K2,403,882
Lara Sullivan
President and CEO, Director
Sep 14, 2023Sale−100$2.25$2252,412,423
Lara Sullivan
President and CEO, Director
Sep 13, 2023Tax withholding−184,742$2.13$393.50K2,412,523
Lara Sullivan
President and CEO, Director
Sep 13, 2023Sale−3,000$2.27$6.81K2,597,265
Lara Sullivan
President and CEO, Director
Sep 12, 2023Sale−4,917$2.25$11.06K2,600,265
Lara Sullivan
President and CEO, Director
Sep 11, 2023Sale−20,000$2.27$45.40K2,605,182
Pamela Ann Connealy
CFO and COO
Sep 7, 2023Award+187,793––782,106
Jitendra Wadhane
Chief Accounting Officer
Sep 7, 2023Award+93,896––211,937
Lara Sullivan
President and CEO, Director
Sep 7, 2023Award+469,483––2,625,182
Jay Feingold
Chief Medical Officer
Mar 24, 2023Award+209,803––730,345
Lara Sullivan
President and CEO, Director
Mar 24, 2023Award+703,379––2,155,699
Pamela Ann Connealy
CFO and COO
Mar 24, 2023Award+209,803––594,313
John L. Flavin
Director
Mar 24, 2023Award+139,355––377,796
Freda C. Lewis-Hall
Director
Mar 24, 2023Award+139,355––206,186
Rachel Humphrey
Director
Mar 24, 2023Award+58,064––58,064
Darren S. Cline
Director
Mar 24, 2023Award+139,355––216,186
Jitendra Wadhane
Chief Accounting Officer
Mar 24, 2023Award+45,000––88,648
Jitendra Wadhane
Chief Accounting Officer
Mar 24, 2023Award+29,393––118,041
Thomas Civik
Director
Mar 24, 2023Award+139,355––206,186
Inc Pfizer
10% owner
Mar 17, 2023Buy+1,811,594$2.76$5.00M5,952,263
Inc Pfizer
10% owner
Mar 17, 2023Buy+1,811,594$2.76$5.00M5,952,263
Jay Feingold
Chief Medical Officer
Jan 3, 2023Award+53,931––520,542
Pamela Ann Connealy
Chief Financial Officer
Jan 3, 2023Award+43,493––384,510
Lara Sullivan
Chief Executive Officer, Director
Jan 3, 2023Award+95,684––1,452,320
Mark Chin
–
Apr 21, 2022Sale−1,745,761$3.05$5.32M0
Jay Feingold
Chief Medical Officer
Apr 14, 2022Award+115,931––466,611
Lara Sullivan
Chief Executive Officer, Director
Apr 14, 2022Award+315,273––1,356,636
Pamela Ann Connealy
Chief Financial Officer
Apr 14, 2022Award+93,493––341,017
Darren S. Cline
Director
Mar 31, 2022Award+66,831––76,831
Jay Feingold
Chief Medical Officer
Mar 31, 2022Award+306,930––350,680
Thomas Civik
Director
Mar 31, 2022Award+66,831––66,831
Pamela Ann Connealy
Chief Financial Officer
Mar 31, 2022Award+247,524––247,524
John L. Flavin
Director
Mar 31, 2022Award+66,831––238,441
Freda C. Lewis-Hall
Director
Mar 31, 2022Award+66,831––66,831

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
6.81%
5M shares short
Days to cover
5.8
At 1M shares a day
Change since last report
+4.1%
From 4M shares
Short volume, 20 days
53.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pyxis Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 46,846 shares on Sep 17, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jakob Dupont
Director
Jun 30, 202635,000$107.03KJun 30, 2026Stock Option Exercise
Rachel Humphrey
Director
Apr 21, 202513,896$14.36KApr 21, 2025Restricted Stock Vesting
Rachel Humphrey
Director
Apr 17, 2025200$194Apr 17, 2025Restricted Stock Vesting
Rachel Humphrey
Director
Apr 14, 20251,400$1.36KApr 14, 2025Restricted Stock Vesting
Lara Sullivan
Officer, Director
Sep 18, 20238,541$17.94KSep 18, 2023Restricted Stock Vesting
Lara Sullivan
Officer, Director
Sep 14, 2023100$225Sep 14, 2023Restricted Stock Vesting
Lara Sullivan
Officer, Director
Sep 13, 20233,000$6.82KSep 13, 2023Restricted Stock Vesting
Lara Sullivan
Officer, Director
Sep 12, 20234,917$11.07KSep 12, 2023Restricted Stock Vesting
Lara Sullivan
Officer, Director
Sep 11, 202320,000$45.41KSep 11, 2023Restricted Stock Vesting
Feingold Jay
Former Chief Medical Officer
Sep 5, 202318,109$42.92KSep 5, 2023Option Granted - 08/16/2021
Feingold Jay
Former Chief Medical Officer
Aug 11, 202350,000$126.48KAug 11, 2023Restricted Stock Vesting
Feingold Jay
Former Chief Medical Officer
Aug 1, 202325,000$63.07KAug 1, 2023Restricted Stock Vesting
Feingold Jay
Former Chief Medical Officer
Jul 31, 202325,000$64.60KJul 31, 2023Restricted Stock Vesting
Feingold Jay
Former Chief Medical Officer
Jul 28, 202323,021$56.01KJul 27, 2023Restricted Stock Vesting
Feingold Jay
Former Chief Medical Officer
Jul 27, 202323,021$56.01KJul 27, 2023Restricted Stock Vesting

See a number that looks wrong?